Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-J591 and 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer
NCT03545165Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Apr 2018
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan, 177lu-rosopatamab in prostate cancer (PCa), sponsored by Weill Cornell Medicine. Started Apr 2018; status: terminated.
02
Drugs
lutetium lu 177 vipivotide tetraxetan177lu-rosopatamab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03545165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03545165.